Related Experiment Videos
Should cholesterol be measured in all hypertensives?
I U Haq1, W W Yeo, P R Jackson
1Department of Medicine and Pharmacology, Royal Hallamshire Hospital, Sheffield, UK.
Journal of Human Hypertension
|June 1, 1995
Summary
Routine cholesterol measurement in hypertensive patients is not justified. Current guidelines are incorrect, as lipid changes from common hypertension drugs are minor and do not impact prognosis, and cholesterol levels do not reliably predict cardiovascular risk in this population.
Area of Science:
- Cardiology
- Hypertension Management
- Lipid Metabolism
Background:
- Current hypertension and hyperlipidaemia guidelines recommend cholesterol measurement in all hypertensive individuals.
- This is partly due to concerns that certain antihypertensive agents (thiazides, beta-blockers) may adversely affect lipid profiles.
- The potential benefit of using cholesterol levels to guide treatment or predict risk in hypertension is debated.
Purpose of the Study:
- To evaluate the necessity and clinical utility of routine serum cholesterol measurement in patients with hypertension.
- To assess whether serum cholesterol levels influence the choice of antihypertensive medication or predict cardiovascular risk in hypertensive individuals.
Main Methods:
- Review of existing literature and guidelines regarding hypertension management and lipid measurement.
- Analysis of the impact of low-dose thiazides and beta-blockers on serum lipids and patient prognosis.
- Examination of the predictive value of serum cholesterol for cardiovascular complications in hypertensive populations, stratified by sex.
Main Results:
- Adverse lipid changes associated with low-dose thiazides and beta-blockers are minimal, transient, and do not worsen patient outcomes.
- Serum cholesterol does not reliably predict cardiovascular risk in hypertensive women and offers limited additional predictive value for coronary heart disease in men beyond existing risk factors.
- Dietary interventions for cholesterol reduction are largely ineffective, and lipid-lowering drug benefits only outweigh risks in very high-risk patients (e.g., post-myocardial infarction).
Conclusions:
- Routine measurement of serum cholesterol in all hypertensive patients is not clinically justified based on current evidence.
- Hypertension alone does not confer a high enough risk to warrant drug therapy for cholesterol reduction.
- Current guidelines recommending routine cholesterol screening in hypertensive individuals should be revised.